Lakefront Biotherapeutics (GLPGF) Common Equity (2013 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Common Equity for 14 consecutive years, with $3.8 billion the latest figure, recorded in Q1 2026.

• On a quarterly basis, Common Equity rose 31.77% year-over-year to $3.8 billion in Q1 2026; TTM through Mar 2026 was $3.8 billion, a 31.77% increase from a year earlier, with the FY2025 full-year figure at $3.7 billion, up 16.6% from the prior year.
• Common Equity was $3.8 billion for Q1 2026 at Lakefront Biotherapeutics, up from $3.8 billion in the prior quarter.
• Over five years, Common Equity peaked at $3.8 billion in Q1 2026 and troughed at $2.6 billion in Q4 2022.
• A 5-year average of $3.1 billion and a median of $3.0 billion in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity slipped 14.77% in 2022 and soared 31.77% in 2026, its largest moves.
• Over 5 years, Common Equity stood at $2.6 billion in 2022, then rose by 16.71% to $3.0 billion in 2023, then advanced by 2.92% to $3.1 billion in 2024, then grew by 21.68% to $3.8 billion in 2025, then gained by 1.12% to $3.8 billion in 2026.
• The last three Common Equity figures came in at $3.8 billion (Q1 2026), $3.8 billion (Q4 2025), and $2.9 billion (Q3 2025), per Business Quant data.